The CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.